---
title: "AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293383326.md"
description: "AbbVie Inc. (ABBV) shares rose 1.07% to $256.10, outperforming competitors Johnson & Johnson, Pfizer, and Amgen during a favorable trading session where the S&P 500 and Dow Jones also gained. AbbVie closed 2.12% below its 52-week high of $261.64. Trading volume was lower than the 50-day average."
datetime: "2026-07-21T20:31:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293383326.md)
  - [en](https://longbridge.com/en/news/293383326.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293383326.md)
---

# AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) advanced 1.07% to $256.10 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.89% to 7,509.20 and the Dow Jones Industrial Average rising 0.74% to 52,224.64.

AbbVie Inc. closed 2.12% below its 52-week high of $261.64, which the company achieved on July 2nd.

The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.72% to $250.61, Pfizer Inc. (PFE) rose 0.77% to $24.94, and Amgen Inc. (AMGN) rose 0.57% to $366.24.

Trading volume (4.3 M) remained 2.8 million below its 50-day average volume of 7.1 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 21, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-21-26 1631ET

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial](https://longbridge.com/en/news/293659753.md)
- [AbbVie (NYSE:ABBV) Releases Q2 2026 Earnings Guidance](https://longbridge.com/en/news/291948764.md)
- [7,295 Shares in AbbVie Inc. $ABBV Acquired by Kiley Juergens Wealth Management LLC](https://longbridge.com/en/news/291953575.md)
- [AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.](https://longbridge.com/en/news/285600926.md)
- [AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins](https://longbridge.com/en/news/291175064.md)